ArticleJournal of neurology2017
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The social determinants of health-related quality of life among people with chronic disease: a systematic literature review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy.Journal of neurology · 2026Review
- An Evaluation of the Real-World Effectiveness of Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.Neurology and therapy · 2026Article
- Long-term motor stability but increasing non-motor burden in multifocal motor neuropathy: a 6-year real-world follow-up study during the COVID-19 era.Frontiers in human neuroscience · 2026Article
- Changes in quality of life and work status after surgical management of meralgia paresthetica- an observational cohort study.Brain & spine · 2026Article
- Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.Patient preference and adherence · 2025Article
- Animal models of immune-mediated demyelinating polyneuropathies.Autoimmunity · 2024Review
- Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study.Journal of clinical medicine · 2024Article
- Article
- A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy.Brain and behavior · 2022Article
- Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.Journal of neurology · 2022Article
- Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.Frontiers in neurology · 2022Article
- Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- The influence of the COVID-19 pandemic on patients with chronic inflammatory demyelinating polyradiculoneuropathy.Clinical neurology and neurosurgery · 2021Article
- Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity.Frontiers in neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic disease which can lead to many functional impairments, and like most other chronic disorders it might significantly affect quality of life (QoL). Information about QoL in patients with CIDP from developing countries is still lacking. We, therefore, sought to complete these data mosaic by investigating QoL in patients with CIDP from Serbia and surrounding countries. Our study comprised 106 patients diagnosed with CIDP. QoL was investigated using the Serbian version of the SF-36 questionnaire. The Medical Research Council 0-5 point scale, INCAT motor and sensory scores, Krupp's Fatigue Severity Scale, and Beck Depression Inventory were also used. Factors that significantly correlated with SF-36 total score in univariate analysis were included in the multiple linear regression analysis. Physical domains of the SF-36 were more affected than mental, and the overall score was 56.6 ± 25.4. Significant predictors of worse SF-36 score in our patients with CIDP were severe fatigue (β = - 0.331, p < 0.01), higher INCAT motor score (β = - 0.301, p < 0.01), depression (β = - 0.281, p < 0.01), being unemployed/retired (β = - 0.188, p < 0.05), and shorter duration of CIDP (β = + 0.133, p < 0.01). QoL was reduced in CIDP patients, especially in physical domains. Patients with presence of fatigue and depression, with more severe motor disability, unemployed/retired ones, and those with shorter duration of the disease need special attention of clinicians since they could be at higher risk to have worse QoL.
Indexed as
Identifiers
29086018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.